Movithiol (Betamethasone Valerate)

Betamethasone Valerate penetrates the skin and binds to intracellular glucocorticoid receptors. This complex alters gene transcription, leading to decreased synthesis of pro‑inflammatory cytokines and mediators, reduced leukocyte migration, and suppression of local immune responses, thereby providing anti‑inflammatory and immunosuppressive effects.

The exact dose and frequency of Movithiol are determined by the prescribing healthcare professional based on the severity of the skin condition, the area to be treated, patient age and other clinical factors. Patients should follow the prescriber’s instructions and not alter the regimen on their own.

Safety data for Betamethasone Valerate in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Healthcare providers should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing individuals.

To request Movithiol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Movithiol (Betamethasone Valerate) is a medium‑ to high‑potency corticosteroid, offering stronger anti‑inflammatory action than low‑potency agents such as hydrocortisone, but with a lower risk of systemic effects compared with very high‑potency steroids like clobetasol. Choice depends on disease severity, treatment area and physician judgment.

Store Movithiol at ambient (room) temperature, preferably below 25 °C. Keep the tube or container tightly closed, protect it from moisture, direct sunlight and extreme temperatures. Do not freeze the product, and retain it in the original packaging until use.

Movithiol is applied topically to the affected skin area. The prescribed amount is usually a thin layer, gently massaged into clean, dry skin once or twice daily, or as directed by the prescriber. Hands should be washed before and after application, and the treated area should be covered only if advised.

Serious risks, though uncommon, include skin atrophy, telangiectasia, and secondary infections (bacterial, fungal or viral) due to local immunosuppression. Prolonged or extensive use can also lead to systemic absorption, potentially causing adrenal suppression. Patients should report any unusual skin changes or signs of infection promptly.

Movithiol should be avoided in individuals with known hypersensitivity to Betamethasone Valerate or any excipients, in skin areas with untreated bacterial, viral or fungal infections, and on mucous membranes or large open wounds unless specifically instructed by a physician. Caution is also advised for children and immunocompromised patients.